港股異動 | 君實生物(1877.HK)逆勢漲近7% 創兩個月新高
格隆匯12月22日丨君實生物(1877.HK)逆勢漲6.85%,報53港元創兩個月新高,暫成交8804.6萬港元,總市值695億港元。君實生物A股漲2.5%。君實生物於日前榮獲“新經濟生物科技公司獎”。公司具備完整的藥物創新全產業鏈能力,服務從全球臨牀研究和開發至大規模商業化生產,而公司致力於源頭創新及合作開發的形式來研發First-in-class (同類首創) 或 Best-in-class (同類最優) 的藥物。匯豐前海本月初認為,與中國龍頭藥企當前平均10倍的2022年預測市銷率相比,君實生物享有更高估值是合理的,因為在新藥放量推動下,公司擁有顯著更高的增長率。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.